JP Morgan Chase’s Genelux GNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$789 Buy
343
+317
+1,219% +$864 ﹤0.01% 7150
2025
Q4
$113 Sell
26
-2,920
-99% -$15.8K ﹤0.01% 7200
2025
Q3
$12.4K Buy
2,946
+2,620
+804% +$9.31K ﹤0.01% 6590
2025
Q2
$936 Hold
326
﹤0.01% 6630
2025
Q1
$880 Hold
326
﹤0.01% 6642
2024
Q4
$769 Hold
326
﹤0.01% 6760
2024
Q3
$773 Hold
326
﹤0.01% 6748
2024
Q2
$636 Sell
326
-7,304
-96% -$24.8K ﹤0.01% 6662
2024
Q1
$49.1K Sell
7,630
-4,644
-38% -$42.2K ﹤0.01% 5952
2023
Q4
$172K Sell
12,274
-319
-3% -$5.04K ﹤0.01% 5473
2023
Q3
$308K Buy
12,593
+10,388
+471% +$263K ﹤0.01% 4771
2023
Q2
$72.1K Buy
2,205
+2,105
+2,105% +$59.2K ﹤0.01% 5611
2023
Q1
$3K Buy
+100
New +$1.62K ﹤0.01% 6341

Other funds holding GNLX

JP Morgan Chase's GNLX Position: Q1 2026 in Review

JP Morgan Chase increased its Genelux (GNLX) stake by 1,219% in Q1 2026, buying an estimated $864 and bringing the position to 343 shares worth $789. The position accounts for ﹤0.01% of the portfolio, ranked #7150.

JP Morgan Chase first reported a position in GNLX in Q1 2023 and has held it in 13 quarters since. The position peaked at $308K in Q3 2023. 71 funds tracked by Wall St. Rank hold GNLX as of Q1 2026.

  • JP Morgan Chase held 343 shares of Genelux worth $789 as of Q1 2026.
  • JP Morgan Chase bought 317 Genelux shares in Q1 2026, an estimated $864.
  • Genelux made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7150 holding.
  • JP Morgan Chase first reported a position in Genelux in Q1 2023 and has held it in 13 quarters since.
  • JP Morgan Chase's Genelux position peaked at $308K in Q3 2023.
  • 71 funds tracked by Wall St. Rank held Genelux as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.